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Introduction
There is still concern regarding potential health effects
of nano-sized and nano-structured materials (NMs).
Since reliable risk assessment is essential for sustained
societal acceptance, there has been substantial funding
for toxicological studies in the past decades. Albeit a
wealth of data has been published since, the relevance of
those data for risk assessment can be questioned. This is
particularily the case for data from studies that focused
on inhalation as the route of exposure. The derivation of
exposure limits for NMs is still an elusive issue, although
some regulatory measures have been undertaken e.g. for
inhalation of carbon nanotubes at the workplace [1].
Today, one of the main obstacles for risk assessment
of nano- and micronsized particles and fibres is not the
lack of toxicological data, but a shortage of data meeting
all of the criteria for use in risk assessment. One of the
most important criteria is accurate dosimetry. While
most studies provide accurate data on particle exposure
concentration, i.e. mass of particles per volume air (μg/
m3) or – for in vitro submerged cell-based assays – per
volume cell culture medium (μg/cm3), the pivotal role of
dose delivered to the site of exposure (e.g. lung epithe-
lium (in vivo) or lung cell culture (in vitro)) has been
widely overlooked. This is especially the case in - but
not limited to - studies with in vitro cell systems [2, 3].
In addition, the choice of consistent and relevant dose
metrics (e.g. mass, volume, surface area, number) has
also been identified as one of the key issues for limited
applicability of toxicological data for risk assessment [4].
While this is beyond the scope of this editorial, we men-
tion that current results indicate that – in addition to
mass, the traditionally used metric – at least one more
dose metric should be used such as surface area, volume
or number, depending on the type of NM [5–7]. This
editorial highlights the fundamental role of delivered
particle dose (sometimes also referred to as internal
dose) for translation of toxicological dose-response data
into risk assessment and exposure limits. The concept of
delivered dose is of overarching significance for any type
of particle exposure scenario. For simplicity we are fo-
cusing on poorly soluble particles (PSP) and models for
respiratory toxicity assessment, i.e. inhalation exposure
for in vivo studies and cell culture exposure under sub-
merged or air-liquid interface conditions.
Exposure or dose: Two sides of the same “coin” in
PSP risk assessment
Often, exposure is considered an acceptable measure for
dose in hazard and risk assessment studies. One of the
reasons for this false perception lies in the different per-
spectives on risk taken by the regulatory body and the
toxicological community. In contrast to exposure con-
centration, delivered dose is often difficult to measure
and real-time dose measurement devices are often not
available at all. For practical reasons, regulatory mea-
sures of health protection have to set limits based on
readily measurable quantities of exposure, namely expos-
ure concentration levels (“exposure limit”). Ideally, these
exposure limits can be adjusted to any substance by de-
termination of material-specific hazard factors. This con-
cept of hazard-based risk assessment is often presented
in a simplified form describing risk as a function of ex-
posure and hazard (risk=f[exposure, hazard]). However,
this is misleading, since exposure to an aerosol of PSP is
a poor predictor of delivered dose (see Fig. 1) and from
a toxicological point of view only the delivered dose, i.e.
the dose which comes into contact with an organism,
can do harm. For inhalation the dose of PSP is strongly
dependent on many factors including respiratory param-
eters (tidal volume, breathing frequency) and PSP-lung
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deposition which depends on PSP characteristics affect-
ing the diffusive (mobility) and aerodynamic behaviour
of PSP (size, density and shape) [8]. Hence, the relevant
measure for toxicological dose-response analysis with
relevance for human risk assessment can only be deliv-
ered dose – not exposure. For definition of exposure
limits, dose-based toxicological results have to be trans-
lated into equivalent exposure limits as described below.
The role of delivered dose for risk assessment
As mentioned above reliable risk assessment of PSP
hinges on (delivered) dose-response relationships mostly
obtained from animal inhalation experiments. Derivation
of dose-based Low or No Observed Adverse Effect
Levels (LOAEL/NOAEL) and related human exposure
limits require extrapolation of LOAEL/NOAEL from
animal/cell to human conditions taking into account
aerosol processing mechanisms and factors determining
the relationship between inhaled concentration and
delivered dose (see Fig. 1) [9–11]. Importantly, inter-
species dose conversion (allometric scaling) requires
appropriate normalization of the delivered dose. For in-
haled PSP this is typically done based on mass of the lung
or surface area of the lung epithelium (in vitro: surface
area of cell culture system), i.e. ideally the normalized de-
livered dose should be presented in terms of μg/cm2-tissue
(lung epithelium) or μg/g-lung (e.g. wet lung weight of
mouse and rat vary around 0.18 and 1.3 g, respectively
[10]. It is noteworthy, that allometric scaling is often based
on body weight, but for inhaled substances surface area
(or mass) of the lung is more relevant than body weight
[7].
Due to practical reasons most animal inhalation studies
report dose-response relationships and NOAEL/LOAEL
in terms of retained dose, i.e. delivered dose corrected for
PSP clearance from the lung due to mucociliary and
macrophage activity [12]. To the best of our knowledge, it
has not been investigated whether delivered or retained
dose of PSP is more predictive for adverse health out-
come. For humans and commonly used animal models
the PSP clearance rates are well known and incorporated
in computational dosimetry models (e.g. ICRP, MPPD)
allowing for easy conversion from delivered to retained
dose, if the exposure regiment (timing) and rate of deliv-
ered dose are known [13, 14]. Hence, at this time both de-
livered and retained dose are acceptable, but should be
clearly identified and all parameters for conversion into
each other should be documented.
As a consequence, derivation of human exposure limits
from toxicological studies relies on dose-response data in
terms of normalized delivered dose, not in terms of expos-
ure. In other words, exposure-response curves in animal
Fig. 1 Normalized delivered dose (dose per surface area or mass of lung/tissue) and not exposure plays the pivotal role for derivation of human
exposure limits from toxicological inhalation studies. The main factors influencing conversion of PSP aerosol exposure concentration into (lung-)
delivered dose are depicted for animal inhalation experiments and factors relevant for extrapolation of No or Low Observed Adverse Effect Levels
(NOAEL/LOAEL) from animal models to humans are highlighted
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or cell models do not allow for direct conclusions on hu-
man exposure limits, i.e. for any toxicologically equivalent
normalized dose the corresponding exposure levels in ani-
mals and humans are different (Fig. 1).
The concept of delivered dose in in vitro studies
Historically, mainly in vivo animal studies were used for
derivation of exposure limits and hazard factors, while
in vitro cell models mainly contributed to identification
and understanding of toxicological pathways. With the
advent of more complex in vitro models of the lung and
other organs, as well as from the perspective of the 3R
principles of more ethical animal testing (calling for re-
finement, reduction and replacement of animal testing),
in the future a more significant role of in vitro testing
for risk assessment of particles and nanomaterials can be
expected.
In principle, two types of in vitro particle exposure
systems can be distinguished. Either aerosolized particles
are deposited directly onto cell models of the lung cul-
tured at the air-liquid interface (ALI) or particles are
suspended in cell culture medium and incubated with
cells under submerged culture conditions, i.e. cells are
completely covered with particle-laden cell culture
medium. Clearly, ALI exposures are mimicking the
physiologic conditions in the lung more realistically and
are therefore potentially more predictive for inhaled par-
ticles [12, 15]. Moreover, under ALI conditions the (nor-
malized) delivered dose can be either determined
directly using e.g. quartz crystal microbalances (QCMs)
[16] or predicted by computational or semi-empirical
aerosol deposition models taking into account all rele-
vant aerosol properties and the experimental characteris-
tics of each exposure system [13, 14]. On the other
hand, exposures under submerged conditions are rela-
tively easy to perform by just adding a known amount of
PSP to cell culture medium. However, this is deceiving,
since a substantial amount of effort has to go into prep-
aration of stable particle suspensions and – even more
problematic – into determination of the fraction of the
administered dose (dose added to the medium) which is
finally delivered to the cells [17, 18]. In the past, the
preference of delivered dose over administered dose has
been largely ignored or overlooked and only recently
practical tools for determination of the (normalized) de-
livered dose in submerged cell systems have been pre-
sented [19, 20]. However, validation of these dosimetry
models is hampered by uncertainty if cellular uptake of
PSP is required for toxicological response or if contact
between the cell membrane and PSP may be enough for
stipulating toxicological response. Nevertheless, partico-
kinetics models or cellular uptake/delivery measure-
ments are currently recommended for estimation of the
delivered dose.
To avoid uncertainties with particokinetics models, the
delivered dose should be measured directly. In principle
this is easily possible for in vitro air-liquid interface cell
exposure experiments (e.g. QCM) and somewhat more
complicated for in vivo animal and submerged in vitro
cell experiments, but material-specific limitations may
apply e.g. for carbonaceous PSP, which are difficult to
detect in (carbon-dominated) biological matrices. Alter-
natively, the delivered dose can be inferred from the ex-
posure concentration and particle deposition models, if
a set of five to seven parameters is known, which de-
pends on the type of exposure scenario as presented in
Fig. 2. In all of these scenarios, the exposure concentra-
tion is multiplied by the volume of air (or cell culture
medium) to calculate the administered dose which is
subsequently converted into delivered dose utilizing
particle-lung deposition models for animal inhalation ex-
periments or particle-cell deposition (particokinetics)
models for in vitro studies with air-liquid interface or
submerged cell culture systems. For all of these three ex-
posure scenarios the main PSP deposition mechanisms
are typically diffusion, sedimentation, interception (rele-
vant for high aspect ratio PSP) and/or impaction as well
as electrophoresis and thermophoresis for some air-
liquid interface cell exposure systems [12, 21]. Any of
these processes can be described using a set of parame-
ters related to either the exposure system or PSP charac-
teristics, namely particle size, shape and density (plus
electrical net charge for electrophoresis). It has been
shown that these three PSP parameters can be lumped
into two directly measurable parameters referred to as
volume-weighted (median) equivalent mobility diameter
and effective mobility density (ratio of PSP mass and
equivalent mobility volume (= π/6 dm
3 , with dm = equiva-
lent mobility diameter) [6]. For easy and reliable partico-
kinetics modelling, both equivalent mobility diameter
and effective mobility density should be stable during
the entire exposure period. As mentioned above, in
addition to these particle characteristics, three to five
exposure-related experimental parameters have to be
reported depending on the exposure setup as specified
in Fig. 2.
Conclusions and recommendations
Delivered dose – not exposure concentration - is abso-
lutely crucial for consistency, risk assessment and regula-
tory relevance of inhalation particle toxicological studies,
since it allows for inter-comparability between in vivo and
in vitro data, read-across analysis (prediction of effects of
the same (or similar) chemical entity with varying physical
characteristics), and extrapolation of cell or animal data to
human exposure conditions and subsequent conversion to
exposure limits.
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From this conclusion the following recommendations
can be derived for studies on inhalation toxicology of
poorly soluble particles (PSP):
 Cell/lung delivered PSP dose should be determined
and normalization of dose to cell/lung surface area is
essential for extrapolation of dose levels from cell
culture or animal models to humans.
 In addition to mass, which is still the most relevant
metric for regulatory purposes, a biologically more
relevant dose metric should be chosen. For non-
fibre-specific toxicity, BET surface area seems to
emerge as the most promising metric, but no final
recommendation can be made at this time.
 If only concentration instead of delivered dose can
be provided, sufficient physical characterisation of
the PSP and the experimental conditions has to be
provided to allow for conversion from concentration
to dose (see Fig. 2).
 Likewise, for in vitro PSP exposures with submerged
cell culture systems normalized delivered dose is the
relevant measure for extrapolation to humans.
Hence, either the delivered dose shoud be
determined experimentally or the following
parameters should be reported for submerged cell
culture studies:
○ All relevant experimental parameters for
conversion of particle concentration (μg/ml-medium)
into administered dose (μg/cm2-cells) should be
reported, namely exposure concentration in cell
culture medium and medium filling height (derived
from cell covered area and medium volume per well)
(Fig. 2).
○ State-of-the-art methods should be used for
conversion of administered to delivered dose and all
relevant experimental parameters for conversion of
administered to delivered dose should be reported
[18]. Currently, the most widely used set of parame-
ters is volume-weighted equivalent mobility diam-
eter and effective mobility density (ratio of mass and
mobility-diameter-based volume assuming spherical
particle shape) (Fig. 2).
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Fig. 2 Required sets of experimental parameters for conversion of poorly soluble particle (PSP) exposure concentration into normalized delivered
dose using particle-lung deposition and particokinetics models for in vivo inhalation (e.g. MPPD V3.04, [13]) and in vitro exposures under air-liquid
interface [9] or submerged exposure conditions (ISDD model, [14, 19]). The list of required parameters (without repetitions) is given in bold letters
for each of the three exposure scenarios. As caveat we add that toxicological measurements should be performed under stable particokinetic
conditions, i.e. both mobility diameter and effective mobility density should be constant during the exposure time
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